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Summary
Background An affordable pneumococcal conjugate vaccine (PCV) is needed to ensure sustainable access in 
low-income and middle-income countries. This trial examined the immunogenicity and safety of a novel ten-valent 
PCV (SIIPL-PCV) containing serotypes 1, 5, 6A, 6B, 7F, 9V, 14, 19A, 19F, and 23F compared with the pneumococcal 
polysaccharide protein D-conjugate vaccine (PHiD-CV; Synflorix; GlaxoSmithKline; Brentford, UK).
Methods In this single-centre, randomised, double-blind, phase 3, non-inferiority trial in The Gambia, healthy, 
PCV-naive infants aged 6–8 weeks were enrolled and assigned using permuted block randomisation to receive one of 
three lots of SIIPL-PCV or to PHiD-CV in a ratio of 2:2:2:3. Parents and all staff assessing study outcomes were masked 
to group assignment. Vaccines (0·5 mL SIIPL-PCV or 0·5 mL PHiD-CV) were administered at ages 6, 10, and 14 weeks 
by intramuscular injection. Primary immunogenicity outcomes, measured at age 18 weeks, were serotype-specific IgG 
geometric mean concentrations (GMCs) and seroresponse rates (IgG ≥ 0·35 μg/mL). Lot-to-lot equivalence (objective 1) 
was shown if the upper and lower bounds of the two-sided 95% CI around the GMC ratio for each pairwise lot-to-lot 
comparison was between the 0·5 and 2·0 equivalence margins for all ten serotypes. The immunogenicity of SIIPL-PCV 
was defined as being non-inferior to that of PHiD-CV (objective 2) if, for at least seven of the ten serotypes in SIIPL-PCV, 
the lower bound of the 97·5% CI for the GMC ratio was greater than 0·5, or the lower bound of the 97·5% CI for 
differences in seroresponse rate was greater than –10%. The GMC and seroresponse rates to serotypes 6A and 19A, 
which are not in PHiD-CV, were compared with those of the serotype in PHiD-CV that had the lowest seroresponse 
rate. Non-inferiority of the immune responses to antigens in the co-administered Expanded Programme on 
Immunization (EPI) vaccines (objective 3) was declared if the lower bound of the 95% CI for the difference between 
SIIPL-PCV and PHiD-CV in seroresponse rates, or GMC ratios for pertussis antigens, was greater than –10% (or 
0·5 for pertussis antigens) for all vaccine antigens. Safety data were assessed according to treatment received at the 
first visit in infants who received at least one dose of study vaccine and for whom at least some post-vaccination safety 
data were available. The primary immunogenicity analysis was in the per-protocol immunogenicity population, which 
included infants who received all study vaccines and had immunogenicity measurements after vaccination and no 
major protocol deviations. This trial is registered at ClinicalTrials.gov (NCT03197376).
Findings Between June 21, 2017, and Jan 29, 2018, 2250 infants were enrolled and randomly assigned to receive SIIPL-PCV 
(n=1503; 502 to lot 1, 501 to lot 2, and 500 to lot 3) or PHiD-CV (n=747). 1458 (97·0%) infants assigned to SIIPL-PCV and 
724 (96·9%) assigned to PHiD-CV were included in the per-protocol primary immunogenicity analysis. Lot-to-lot 
equivalence was shown, with the lowest lower bound of the 95% CI for the GMC ratio being 0·52 (for serotype 6B in lot 2 
vs lot 3) and the highest upper bound being 1·69 (for serotype 6B in lot 1 vs lot 2). SIIPL-PCV was non-inferior to 
PHiD-CV in terms of immunogenicity: the lower bound of the 97·5% CI for the GMC ratio was greater than 0·5 (the 
lowest being 0·67 for serotype 19F) and the lower bound of the 97·5% CI for the difference in seroresponse rate was 
greater than –10% (the lowest being –2·2% for serotype 6B) for all ten serotypes in SIIPL-PCV. The lowest seroresponse 
rate after PHiD-CV was to serotype 6B (76·7% [95% CI 73·4–79·7]). This serotype was therefore used for the comparisons 
with serotype 6A and 19A in SIIPL-PCV. Non-inferiority of immune responses to the EPI vaccines after co-administration 
with SIIPL-PCV compared with after co-administration with PHiD-CV was shown for all vaccine antigens included in 
the primary series. The lowest lower bound of the 95% CI for the difference in seroresponse rates was –7·1% for rotavirus 
antibody and for the GMC ratio for pertussis antigens was 0·62 for anti-pertussis toxoid. 1131 (75·2%) of 1503 infants in 
the SIIPL-PCV group and 572 (76·6%) of 747 in the PHiD-CV group had at least one unsolicited adverse event. 
36 (2·4%) participants in the SIIPL-PCV group and 18 (2·4%) in the PHiD-CV group had a serious adverse event; none 
were considered related to vaccination. In infants who were selected to have solicited adverse events recorded, injection-
site induration after primary vaccinations occurred in 27 (4·9%) of 751 infants who received SIIPL-PCV versus 34 (9·4%) 
of 364 who received PHiD-CV (p=0·0032). There were no other notable differences in the safety profiles of the 
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two vaccines. One infant in the SIIPL-PCV group and two in the PHiD-CV group died during the study. The deaths were 
not considered to be related to study vaccination or study participation.
Interpretation The immunogenicity of SIIPL-PCV was non-inferior to that of PHiD-CV, for which efficacy and 
effectiveness data against pneumococcal disease are available. The vaccine is safe and can be co-administered with 
routine EPI vaccines. The data generated in this trial have supported the licensure and pre-qualification of SIIPL-PCV, 
making the vaccine available for introduction into national immunisation programmes. Generating post-
implementation data confirming vaccine impact remains important.
Funding Bill & Melinda Gates Foundation.
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Pneumonia is the leading cause of under-5 mortality 
beyond the neonatal period worldwide, and the leading 
cause of all under-5 mortality in sub-Saharan Africa. It 
caused an estimated 900 000 deaths worldwide in this 
age group in 2015.1,2 Streptococcus pneumoniae is the most 
Research in context
Evidence before this study
We searched PubMed to identify articles published before 
April 1, 2020, using the following search terms with appropriate 
Boolean operators: ”pneumococcal conjugate vaccin*”, 
”pneumococcal vaccin*”, ”immun*”, ”meta-analysis”, 
”systematic review”, ”randomized controlled trial”, ”clinical trial”, 
“efficacy”, ”effectiveness”, ”impact”, and ”safety”. Only 
three pneumococcal conjugate vaccines (PCVs) from 
two manufacturers in high-income countries had been licensed 
and WHO prequalified for purchase by Gavi-eligible countries 
before this study: the first-generation seven-valent vaccine 
(Prevenar, Pfizer) and two second-generation vaccines, 
including the pneumococcal polysaccharide protein D-conjugate 
vaccine (PHiD-CV; Synflorix, GSK), ten-valent PCV, and the 
13-valent PCV (Prevenar 13, Pfizer). All three vaccines are safe on 
the basis of both randomised controlled trials (RCTs) and post-
licensure pharmacovigilance data. Meta-analyses of RCTs 
indicate that the pooled efficacy of PCVs against vaccine-type 
invasive pneumococcal disease (IPD) is at least 80%, and against 
all IPD (vaccine type and non-vaccine type) is around 60%. The 
pooled efficacy of the vaccines against radiologically confirmed 
pneumonia is about 30% and against clinical pneumonia is 
between 5% and 10%. The vaccines reduce the incidence of 
pneumococcal acute otitis media after administration in infancy 
by between around a quarter and a half, whereas their effect on 
all-cause and recurrent acute otitis media is uncertain. An effect 
of the vaccines on all-cause mortality has also been shown in 
some RCTs, including a trial done in The Gambia, although 
meta-analyses have not shown a significant effect of the PCVs 
on this endpoint overall. Effectiveness data generated after 
vaccine licensure are heterogenous according to study design, 
schedule, and setting. The effectiveness of the vaccines against 
vaccine-type IPD ranges from about 75% to almost 100%. 
The vaccines reduced radiologically confirmed pneumonia by 
between a third and two-thirds and clinical pneumonia by less 
than a fifth in some studies and by more than two-thirds in 
others. No substantial differences in effectiveness between the 
two second-generation vaccines on disease endpoints have 
been shown. PHiD-CV, the reference vaccine used in this trial, 
was licensed on the basis of non-inferiority of the serotype-
specific IgG seroresponse rates generated by the vaccine to 
those generated by the seven-valent PCV. However, the vaccine 
has subsequently been shown to have an efficacy of 100% 
against vaccine-type IPD and of 18% against community-
acquired pneumonia in RCTs and to have significant effects on 
pneumococcal disease endpoints in post-licensure effectiveness 
studies, including studies done in sub-Saharan Africa.
Added value of this study
The candidate ten-valent PCV, SIIPL-PCV, includes the 
dominant pneumococcal serotypes causing disease in 
low-income and middle-income countries. The vaccine met 
the criteria set out in the WHO Technical Report Series for the 
clinical assessment of PCVs and the target product profile, 
which defines the specifications new PCVs must meet to secure 
future purchase for Gavi-eligible countries. After a three-dose 
primary series, given at ages 6, 10, and 14-weeks, the 
immunogenicity of SIIPL-PCV was non-inferior to that of 
PHiD-CV. The vaccine can be co-administered with routine 
EPI vaccines and has a similar safety profile to that of PHiD-CV. 
A robust response to a booster dose of the vaccine given at age 
9 months and high functional opsonophagocytic activity 
antibody titres both after the primary vaccinations and after 
the booster vaccination were also demonstrated.
Implications of all the available evidence
Based on these data, SIIPL-PCV has been prequalified by WHO. 
The vaccine is therefore available to Gavi-eligible countries 
and for purchase by the UN and other agencies. The addition 
of SIIPL-PCV to the pool of available PCVs is expected to 
accelerate PCV rollout and ensure programme sustainability, 
further reducing vaccine-preventable pneumococcal disease 
worldwide. Demonstration of non-inferiority and the comparable 
distribution of antibody concentrations suggests SIIPL-PCV will 
have a similar effect on pneumococcal disease to PHiD-CV.
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common cause of pneumonia-associated morbidity and 
mortality. More than 300 000 children die from pneu-
mococcal pneumonia, meningitis, and other invasive 
pneumococcal diseases (IPDs) each year.3 Most of these 
deaths occur in a small number of low-income and 
middle-income countries (LMICs).2,3 There are more 
than 90 serotypes of S pneumoniae, but a relatively small 
number are responsible for the majority of disease, and 
there are important geographical differences in their 
distributions.4
Pneumococcal conjugate vaccines (PCVs) are highly 
effective at preventing serotype-specific pneumococcal 
disease, and their introduction has led to substantial 
reductions in morbidity and mortality associated with 
pneumococcal infection—including in The Gambia where 
this trial was conducted.5,6 However, PCVs are available 
from only two manufacturers and are unaffordable for 
many low-income countries without financial support 
from Gavi, the Vaccine Alliance.7 The organisation is 
expected to spend more than 40% of its budget on PCVs 
between 2016 and 2020, equivalent to US$2·8 billion.8 
Pricing also places considerable financial burden on 
middle-income countries ineligible for, or transitioning 
from, Gavi support.7 Consequently, the availability of an 
additional safe, effective, more affordable PCV that targets 
serotypes most prevalent in LMICs is expected to enhance 
programme sustainability in those settings where the 
disease burden is highest.7
The ten-valent candidate PCV developed by Serum 
Institute of India (SIIPL-PCV) includes the dominant 
disease-causing serotypes in Africa, Asia, and Latin 
America (1, 5, 6A, 6B, 7F, 9V, 14, 19A, 19F, and 23F) and 
offers similar coverage to the licensed PCVs in these 
regions.4 In phase 1/2 trials done in The Gambia and India, 
SIIPL-PCV had a reassuring safety profile in adults, 
toddlers, and infants. The vaccine was immuno genic 
for all ten serotypes in the three age-groups, including 
when co-administered with Expanded Pro gramme on 
Immunization (EPI) vaccines.9,10
This phase 3 trial was designed to meet the criteria 
specified in the WHO Technical Report Series for the 
clinical assessment of PCVs, alongside the target product 
profile for the advanced market commitment for PCVs, 
which defines the specifications new vaccines must meet 
to secure purchase for Gavi-supported countries.11,12 The 
study had three primary immuno genicity objectives. First, 
to establish the equivalence of the immune responses 
generated by three lots of SIIPL-PCV. The three lots 
(manufacturing batches) were produced at commercial 
scale, based on a plan approved by the WHO before the 
start of the study. Second, to show non-inferiority of the 
immune response induced by SIIPL-PCV compared with 
the immune response induced by the pneumococcal 
polysaccharide protein D-conjugate vaccine (PHiD-CV; 
Synflorix; GlaxoSmithKline; Brentford, UK), a licensed 
ten-valent PCV. Third, to confirm the non-inferiority of the 
immune responses generated by routine EPI vaccines 
when co-administered with SIIPL-PCV compared with 
PHiD-CV as part of the primary series.
Given the value an additional PCV is expected to 
bring to the global market, and the high efficacy of the 
available vaccines, the primary immunogenicity 
analyses were for non-inferiority. PHiD-CV, rather than 
the 13-valent PCV (Prevenar13, Pfizer [PCV13]), was 
used as the reference vaccine. The choice was made 
because the efficacy of PHiD-CV against IPD, 
pneumonia, and otitis media in infants and children 
has been established in randomised controlled trials 
done in Europe and South America.13,14 The vaccine has 
also been shown to be highly effective at preventing 
IPD and pneumonia in infants in Kenya—also based 
on a 6-week, 10-week, and 14-week schedule.15,16 Thus, 
confirmation that SIIPL-PCV has non-inferior immuno-
genicity to PHiD-PCV supports the expected effect of 
the vaccine on IPD, for which an immunological 
correlate of protection exists.12 Descriptive comparisons 
allow the protection the vaccine is expected to confer 
against other pneumococcal disease endpoints to be 
estimated. Furthermore, although the post-primary 
seroconversion rates and effect on vaccine-type IPD are 
consistently high after both vaccines, the IgG geometric 
mean concentrations (GMCs) generated by PHiD-CV 
tend to be lower than those generated by PCV13.17–20  
Methods
Study design and participants
This was a single-centre, randomised, double-blind, 
phase 3, non-inferiority trial. Healthy, PCV-naive infants 
aged 6–8 weeks were enrolled at Medical Research 
Council (MRC) clinical trial facilities within three 
government health centres (Faji Kunda Health Centre, 
Brikama Health Centre, and Bundung Maternal and 
Child Health Hospital) in the peri-urban western region 
of The Gambia. To be eligible, infants had to weigh at 
least 3·5 kg and have no clinically relevant health 
conditions. Full inclusion and exclusion criteria are in 
the appendix (pp 1–3). All parents provided written 
informed consent before any study-related procedures 
took place.
The study was conducted in accordance with the 
Declaration of Helsinki and Good Clinical Practice 
guidelines. Approval was obtained from The Gambia 
Government/MRC joint ethics committee, the Western 
Institutional Review Board, and the Gambian Medicines 
Control Agency.
Randomisation and masking
Eligible infants were assigned to receive either one of 
three lots of SIIPL-PCV or PHiD-CV in a 2:2:2:3 ratio 
using a predefined randomisation scheme. As part of the 
randomisation scheme, half of the infants in each group 
were selected to provide solicited adverse event data after 
the vaccinations at weeks 6, 10, and 14. An independent 
biostatistician generated randomisation sequences using 
See Online for appendix
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permuted blocks with randomly selected block sizes. 
Vaccine assignments were printed on the inside of 
sequentially numbered, sealed, opaque, tamper-evident 
envelopes. Randomisation was done by unmasked 
nurses by opening the next envelope in sequence. The 
same nurses then drew up and administered the vaccines 
using identical syringes, but they were not involved 
in any other participant-related procedures or endpoint 
assessments. Parents and all other trial staff were masked 
to group assignment.
Procedures
The first primary vaccination visit (visit 1) took place when 
the infants were aged 6–8 weeks. Two further primary 
vaccination visits (visit 2 and visit 3) and a follow-up 
immunogenicity visit (visit 4; post-primary visit) took 
place at 4-week intervals. The first 675 infants were also 
enrolled to receive a booster vaccination at age 9 months 
(visit 5) and a final follow-up immunogenicity visit (visit 6; 
post-booster visit) 4 weeks later (appendix, p 4).
A single 0·5 mL dose of SIIPL-PCV (Serum Institute 
of India, Pune, India) contains 2 μg each of serotypes 1, 
5, 6A, 7F, 9V, 14, 19A, 19F, and 23F poly saccharide and 
4 μg of serotype 6B polysaccharide, all individually con-
jugated to recombinant non-toxic diphtheria cross-
reactive material-197 protein and adsorbed onto 
aluminium phosphate. Lots 209Y7001AZ, 209Y7002AZ, 
and 209Y7003AZ were used. A single 0·5 mL dose of 
PHiD-CV (GlaxoSmithKline, Brentford, UK) contains 
1 µg each of serotypes 1, 5, 6B, 7F, 9V, 14, and 23F 
polysaccharide and 3 µg of serotype 4 polysaccharide, all 
individually conjugated to recombinant non-typable 
Haemophilus influenzae protein D, 3 µg of serotype 18C 
polysaccharide con jugated to tetanus toxoid, and 3 µg of 
serotype 19F polysaccharide conjugated to diphtheria 
toxoid, all adsorbed onto aluminium phosphate. Lot 
XSPNA828BB was used.
Infants concomitantly received the routine EPI vacci-
nations according to the schedule in The Gambia 
(appendix p 5). Parenteral vaccines were administered by 
intramuscular injection into the anterolateral aspect of 
the thigh using 23G, 25 mm needles.
The first 450 infants in the SIIPL-PCV group and the 
first 225 infants in the PHiD-CV group who had sufficient 
blood volumes were included in the analysis of EPI 
vaccine responses. The first 250 infants in both the 
SIIPL-PCV and PHiD-CV groups were included in the 
analysis of opsono phagocytic activity (OPA) at visit 4 and 
the first 100 infants in both the SIIPL-PCV and PHiD-CV 
groups were included in the analysis of OPA responses 
at visit 6. At visit 4 and visit 6, 5·0 mL blood samples 
were collected and serum was separated and stored at 
–70°C for immuno genicity testing. PCV immunogenicity 
was assessed by the WHO Pneumococcal Serology 
Reference Laboratory (Great Ormond Street Institute of 
Child Health Biomedical Research Centre, London, UK) 
using a validated ELISA to quantify pneumococcal 
IgG concentrations and a validated multiplex OPA assay 
to assess functional res ponses.21,22 IgG concentrations to 
each component of the co-administered diphtheria, 
tetanus, whole-cell pertussis, hepatitis B, H influenzae 
type b (Hib) vaccine, and to the measles and rubella 
vaccine, and IgA concentrations to rotavirus, were 
measured by ELISA. Neutralising antibody titres were 
measured for polioviruses types 1, 2, and 3 and yellow 
fever virus (appendix p 6).
Solicited injection-site (tenderness, erythema, and indu-
ration) and systemic (cutaneous rash, axillary temperature, 
irritability, drowsiness, and decreased appetite) adverse 
events were recorded after each primary vaccination in all 
infants and, in those infants randomly selected to have 
solicited adverse events collected, daily for the next 6 days 
through home visits. Solicited adverse events were 
collected from all participants after the booster vaccination. 
Parents were also asked to contact the study team with any 
health-related concerns, and their infants were then seen 
by a study clinician who provided any necessary treatment 
and recorded all unsolicited adverse events.
Solicited adverse events were graded for severity from 
grade 1 to grade 4 (appendix p 7). Unsolicited adverse 
events were categorised using Medical Dictionary for 
Regulatory Activities preferred terms, graded from 
grade 1 (mild) to grade 5 (resulted in death), and assessed 
for relatedness to study vaccine by the investigator.
Outcomes
For the assessment of lot-to-lot equivalence (objective 1), 
we assessed serotype-specific GMCs. The primary 
outcome measures for PCV immunogenicity (objective 2) 
were the serotype-specific IgG GMCs and seroresponse 
rates. The seroresponse rate was defined as the proportion 
of infants with serotype-specific IgG concentrations of at 
least 0·35 µg/mL, which is the reference concentration 
for assessment of vaccine efficacy against IPD.12 The 
primary outcome measures for EPI vaccine immuno-
genicity (objective 3), other than for pertussis, were 
seroresponse rates. The primary outcome measures for 
pertussis vaccine immunogenicity were GMCs of anti-
pertussis toxoid IgG and anti-fimbriae 2/3 IgG. All 
primary outcomes were assessed at the primary visit.
Secondary outcome measures were the OPA 
seroresponse rates, defined as the proportion of infants 
with an OPA titre of at least 8, and OPA geometric mean 
titres (GMTs); both were measured at the post-primary 
visit. Another secondary outcome was the ratio of IgG 
GMCs and OPA GMTs measured at the post-booster visit 
to those measured at the post-primary visit. Secondary 
outcome measures for measles, rubella, and yellow fever 
immunogenicity were seroresponse rates at the post-
booster visit (appendix p 6).
Safety outcomes were the number and severity of 
solicited adverse events during the 7 days after each 
vaccination and the number, severity, and relatedness to 
study vaccine of adverse events and serious adverse 
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events throughout the study. A data safety monitoring 
board reviewed safety data and trial conduct throughout 
the trial, first meeting after about a quarter of participants 
had received one dose of the study vaccine.
Statistical analysis
The estimated required sample size of 2250 infants was 
calculated on the basis of an iterative process allowing for 
up to 10% participant attrition from the per-protocol 
population. Based on achieving the lot-to-lot equivalence 
objective, data for all three lots of SIIPL-PCV were to be 
combined in the analysis of further objectives. The 
overall power to achieve the three primary objectives was 
calculated as the product of the individual powers and 
was about 94%. The collection of solicited adverse event 
data on half the infants was judged to provide sufficient 
power to detect clinically significant differences in these 
event rates (appendix pp 8–13).
All three primary immunogenicity objectives had to be 
attained individually for the trial to achieve its overall 
aim. The equivalence and non-inferiority margins used 
were aligned with those used to support licensure of 
the already available PCVs.23–25 To achieve lot-to-lot 
equivalence, the upper and lower bounds of the two-sided 
95% CIs around the GMC ratios for each of the 
three pairwise lot-to-lot comparisons (eg, GMClot1:GMClot2) 
had to be between the 0·5 and 2·0 equivalence margins 
for all ten serotypes. No adjustment for multiplicity was 
made given the requirement to show equivalence for all 
comparisons.
The trial was not designed to establish non-inferiority for 
the immune responses induced by individual serotypes in 
SIIPL-PCV, but rather to show the non-inferiority of the 
immune response induced by SIIPL-PCV compared with 
that induced by PHiD-CV. For SIIPL-PCV to be non-
inferior to PHiD-CV, at least one of the following had to be 
achieved for seven of the ten serotypes included in SIIPL-
PCV: the lower bound of the two-sided 97·5% CI around 
the GMC ratio (GMCSIIPL-PCV:GMCPHiD-CV) for the serotype 
had to be greater than 0·5 or the lower bound of the 
97·5% CI around the difference in the seroresponse rates 
(seroresponse rateSIIPL-PCV – seroresponse ratePHiD-CV) had to be 
greater than –10%. 97·5% CIs were used to adjust for the 
two endpoints by which non-inferiority could be 
established. As recommended by the WHO Technical 
Report Series, GMCs and seroresponse rates for serotypes 
6A and 19A, the non-matched serotypes in SIIPL-PCV, 
were compared with data for the serotype in PHiD-CV 
with the lowest seroresponse rate.12 As a secondary 
objective, the superiority of the seroresponse rates and 
GMCs to serotypes 6A and 19A induced by SIIPL-PCV, 
compared with the crossreactive responses to the same 
serotypes generated by PHiD-CV, were tested. The trial 
was not otherwise designed to draw conclusions regarding 
individual serotypes. However, for the eight serotypes 
shared by both vaccines, we considered CIs around 
2514 infants assessed for eligibility
2250 infants randomly assigned
264 not eligible
 118 low weight or Z score
 95 medical condition or concern
 21 unexplained sibling death
 17 did not meet inclusion criteria or met exclusion criteria
 9 out of age window
 4 withdrawal of consent
1503 randomly assigned to SIIPL-PCV 
 (502 to lot 1, 501 to lot 2, and 500 to lot 3)
 451 in booster cohort
 751 in solicited adverse event cohort
1503 vaccinated with SIIPL-PCV
 (502 received lot 1, 501 received lot 2, 
 and 500 received lot 3)*
45 excluded
 28 did not complete primary 
 vaccination series†
 10 out of window visit
 7 no serology result
1458 in post-primary per-protocol immunogenicity 
 population
 450 assessed for EPI vaccine responses
 250 assessed for OPA responses
428 received booster SIIPL-PCV
425 in the post-booster per-protocol
 immunogenicity population
 425 assessed for EPI vaccine responses
 100 assessed for OPA responses
1030 not included in booster population
 1014 in primary cohort only
 16 did not receive booster 
 vaccination
3 excluded
 1 out of window visit
 2 no serology result 
747 randomly assigned to PHiD-CV
 224 in booster cohort
 364 in solicited adverse event cohort
747 vaccinated with PHiD-CV
23 excluded
 16 did not complete primary 
 vaccination series†
 1 out of window visit
 5 no serology result
 1 violated eligibility criteria
724 in post-primary per-protocol immunogenicity 
 population
 225 assessed for EPI vaccine responses
 250 assessed for OPA responses
213 received booster PHiD-CV
209 included in the post-booster per-protocol 
 booster immunogenicity population
 209 assessed for EPI vaccine responses
 100 assessed for OPA responses
511 not included in booster population
 506 in primary cohort only
 5 did not receive booster
 vaccination
4 excluded
 2 out of window visit
 2 no serology resultFigure 1: Trial profile
SIIPL-PCV=Serum Institute of India candidate ten-valent pneumococcal 
conjugate vaccine. PHiD-CV=pneumococcal polysaccharide protein D-conjugate 
vaccine (Synflorix). EPI=Expanded Programme on Immunization. 
OPA=opsonophagocytic activity. *Data for the three lots were combined in all 
further analyses once lot-to-lot equivalence had been confirmed. †Of these 
infants, seven in the SIIPL-PCV group and six in the PHiD-CV group were also 
assigned to the booster populations.
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seroresponse differences that excluded 0 and around GMC 
or GMT ratios that excluded 1 to be meaningful differences 
for the purpose of descriptive comparison. To show 
non-inferiority of the immune responses to the co-
administered EPI vaccines, the lower limit of the two-sided 
95% CI around the difference in seroresponse rates 
(EPI-seroresponse rateSIIPL-PCV – EPI-seroresponse ratePHiD-CV) 
for diphtheria, tetanus, hepatitis B, Hib, polioviruses 
types 1, 2, and 3, and rotavirus had to be greater than –10%. 
To show non-inferiority of the immune responses to 
pertussis, the lower bounds of the 95% CIs around the 
GMC ratios for anti-pertussis toxoid and anti-fimbriae 2/3 
IgG (eg, anti-pertussis toxoid GMCSIIPL-PCV:anti-pertussis 
toxoid GMCPHiD-CV) had to be greater than 0·5. All EPI 
responses had to be non-inferior to achieve this primary 
objective and therefore no adjustment for multiplicity was 
required.
All CIs around differences in seroresponse rates were 
calculated using the Miettinen-Nurminin likelihood 
ratio score method. Having confirmed the normality 
assumption was appropriate, CIs around GMC ratios 
were calculated on the basis of a normal distribution for 
the log10-transformed antibody concentrations or titres.
Differences in the proportions of participants with 
solicited and unsolicited adverse events were assessed 
using Cochran-Mantel-Haenszel tests, stratified by field 
site, or using Fisher’s exact tests, as appropriate based 
on the number of comparisons being made. Observed 
differences in safety parameters were also assessed for 
medical relevance.
Primary immunogenicity analyses were done on a per-
protocol basis, in infants who received all primary doses of 
study vaccine and had post-dose immunogenicity measure-
ments available with no major protocol deviations. Safety 
data were assessed according to treat ment received at the 
first visit in infants who received at least one dose of study 
vaccine and for whom at least some post-vaccination safety 
data were available. 
Statistical analyses were done with SAS/STAT software 
version 9.4. The trial is registered at ClinicalTrials.gov 
(NCT03197376).
Role of the funding source
The Bill & Melinda Gates Foundation funded PATH to 
conduct this study. PATH was involved in all stages of 
the study conduct, data analysis, and interpretation. All 
authors had full access to all the data in the study and were 
responsible for the decision to submit for publication.
Results
Between June 21, 2017, and Jan 29, 2018, 2514 infants 
were assessed for eligibility (figure 1). Of these, 
2250 (89·5%) infants were enrolled, of whom 
1503 (66·8%) were randomly assigned to receive one of 
the three lots of SIIPL-PCV (502 to lot 1, 501 to lot 2, and 
500 to lot 3) and 747 (33·2%) were randomly assigned 
to receive PHiD-CV. 2182 (97·0%) of 2250 infants, 
including 1458 (97·0%) of 1503 infants in the SIIPL-PCV 
group and 724 (96·9%) of 747 infants in the PHiD-CV 
group, were eligible for inclusion in the per-protocol 
population for assessment of the primary immuno-
genicity objectives. The first 675 infants also received a 
booster dose of their assigned vaccine at age 9 months 
(451 in the SIIPL-PCV group and 224 in the PHiD-CV 
group). Within this group, 634 (93·9%) were eligible for 
inclusion in the per-protocol population for assessment 
of booster responses. The median age at the first study 
vaccination was 46 days (range 42–56 days). There 
were no noteworthy differences in anthropometric or 
sociodemographic characteristics between groups at 
baseline (table 1).
Based on pneumococcal serotype-specific IgG GMCs 
assessed at the post-primary visit, the prespecified lot-to-
lot equivalence criteria were met for all pairwise lot-to-lot 
comparisons, for all ten serotypes (appendix pp 14–15). 
The lowest lower bound of the 95% CI for the GMC ratio 
was 0·52 (for serotype 6B in lot 2 vs lot 3) and the highest 
upper bound was 1·69 (for serotype 6B in lot 1 vs lot 2). 
Thus, lot-to-lot equivalence was confirmed (objective 1) 
and data for the three lots were combined for further 
analyses.
Seroresponse rates at the post-primary visit ranged 





Age at vaccination 1, days 46 (42–56) 46 (42–56)
Sex
Female 738 (49·1%) 347 (46·5%)
Male 765 (50·9%) 400 (53·5%)
Race
African 1502 (99·9%) 747 (100%)
Other 1 (0·1%) 0
Ethnicity
Mandinka 777 (51·7%) 397 (53·1%)
Wolof 156 (10·4%) 61 (8·2%)
Fula 186 (12·4%) 86 (11·5%)
Jola 180 (12·0%) 100 (13·4%)
Other 203 (13·5%) 103 (13·8%)
Weight, kg 4·7 (3·4–6·9) 4·6 (3·5–6·5)
Length, cm 55·5 (47·7–63·4) 55·4 (49·8– 61·5)
Primary cooking fuel source
Wood or charcoal 1491 (99·2%) 734 (98·3%)
Other 12 (0·8%) 13 (1·7%)
Primary water source
Private tap, well, or borehole 958 (63·7%) 473 (63·3%)
Community tap, well, or 
borehole
545 (36·3%) 274 (36·7%)
Data are median (range) or n (%). PHiD-CV=pneumococcal polysaccharide protein 
D-conjugate vaccine (Synflorix). SIIPL-PCV=Serum Institute of India candidate 
ten-valent pneumococcal conjugate vaccine.
Table 1: Baseline characteristics of all infants who received at least 
one vaccine dose
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(76·5–80·7) for serotype 6B after SIIPL-PCV, and 
from 99·0% (98·0–99·6) for serotype 1 to 76·7% 
(73·4–79·7) for serotype 6B after PHiD-CV (figure 2A; 
appendix p 16). The seroresponse rate to serotype 6B was 
the lowest among the eight shared serotypes after 
PHiD-CV, and therefore serotype 6B was used as the 
comparator for serotypes 6A and 19A. The lower bound 
of the 97·5% CI for the difference in seroresponse rates 
was above –10% for all eight shared serotypes and by 
comparison to serotype 6B for serotypes 6A and 19A 
(figure 2A; appendix p 16). Among the shared serotypes, 
seroresponse rates for serotypes 5 and 23F were higher 
after SIIPL-PCV than after PHiD-CV (97·5% CIs 
exclude 0; figure 2A; appendix p 16).
The post-primary GMCs after SIIPL-PCV ranged from 
5·20 µg/mL (95% CI 4·92–5·50) for serotype 14 to 
1·00 µg/mL (0·95–1·06) for serotype 6A, whereas the 
GMCs after PHiD-CV ranged from 5·93 µg/mL 
(5·50–6·39) for serotype 19F to 0·87 µg/mL (0·80–0·95) 
for serotype 23F. The lower bound of the 97·5% CI 
for the GMC ratio was above 0·5 for all eight shared 
serotypes and by comparison to serotype 6B for 
serotypes 6A and 19A (figure 2B; appendix p 16). 
Additionally, among the shared serotypes, the GMCs for 
serotypes 1, 5, 7F, 14, and 23F were higher after 
SIIPL-PCV than after PHiD-CV (97·5% CIs exclude 0; 
figure 2B; appendix p 16). The GMC was higher for 
serotype 19F after PHiD-CV than after SIIPL-PCV. Thus, 
on the basis of seroresponse rates and GMCs, the overall 
non-inferiority of the immune response to SIIPL-PCV 
compared with PHiD-CV was confirmed (objective 2). 
The seroresponse rates and GMCs to serotypes 6A 
and 19A in SIIPL-PCV were also superior to the cross-
reactive responses to serotypes 6B and 19F generated by 
PHiD-CV (appendix p 18).
Seroresponse rates to tetanus, diphtheria, hepatitis B, 
Hib, and polio were high irrespective of whether the 
vaccines were co-administered with SIIPL-PCV or PHiD-
CV (table 2). Rotavirus seroresponse rates were 27·3% 
(95% CI 23·2–31·7) after co-administration with SIIPL-
PCV and 27·1% (21·4–33·4) after co-administration with 
PHiD-CV. For all antigens, the lower bound of the 
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 2·15 (2·00 to 2·32)
 1·37 (1·28 to 1·47)
 1·07 (0·93 to 1·24)
 1·30 (1·19 to 1·41)
 0·92 (0·85 to 1·00)
 1·23 (1·10 to 1·37)
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 1·45 (1·30 to 1·63)
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GMC ratio (SIIPL-PCV/PHiD-CV) (%)
A
B
Figure 2: Non-inferiority analysis for seroresponse rates (A) and GMCs (B) 4 weeks after the three-dose primary vaccination series
The dotted lines show the non-inferiority margins. GMC=geometric mean concentration. PHiD-CV=pneumococcal polysaccharide protein D-conjugate vaccine 
(Synflorix). SIIPL-PCV=Serum Institute of India candidate ten-valent pneumococcal conjugate vaccine.*For serotypes 6A and 19A (which are not included in 
PHiD-CV), seroresponse rates and GMCs for the SIIPL-PCV group were compared with those for the serotype in the PHiD-CV group with the lowest seroresponse 
rate (ie, serotype 6B).
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95% CI for the difference in seroresponse rates was 
greater than –10%. Responses to pertussis in the 
SIIPL-PCV group were non-inferior to those in the 
PHiD-CV group on the basis of GMC ratios. Therefore, 
non-inferiority of the immune responses to all EPI 
vaccines after co-administration with SIIPL-PCV com-
pared with co-administration with PHiD-CV during the 
primary series (objective 3) was demonstrated.
SIIPL-PCV PHiD-CV Difference (95% CI)
EPI vaccine seroresponse after primary vaccination*
Anti-diphtheria toxoid ≥0·1 IU/mL 100% (99·2 to 100; 447/447) 100% (98·4 to 100; 225/225) 0·0%
Anti-tetanus toxoid ≥0·1 IU/mL 100% (99·2 to 100; 447/447) 100% (98·4 to 100; 225/225) 0·0%
Anti-hepatitis B surface antigen concentration 
≥10 mIU/mL
100% (99·2 to 100; 447/447) 99·6% (97·6 to 100; 224/225) 0·4% (–0·4 to 2·5)
Anti-polyribosylribitol phosphate (Haemophilus influenzae 
type b) concentration ≥0·15 μg/mL
98·7% (97·1 to 99·5; 441/447) 99·6% (97·6 to 100; 224/225) –0·9% (–2·5 to 1·2)
Anti-polio neutralising antibody titre >8
Type 1 99·8% (98·8 to 100; 446/447) 100% (98·4 to 100; 225/225) –0·2% (–1·3 to 1·5)
Type 2 83·7% (79·9 to 87·0; 374/447) 80·9% (75·1 to 85·8; 182/225) 2·8% (–3·2 to 9·3)
Type 3 97·8% (95·9 to 98·9; 437/447) 98·7% (96·2 to 99·7; 222/225) –0·9% (–3·0 to 1·8)
Anti-rotavirus antibody concentration ≥20 U/mL 27·3% (23·2 to 31·7; 122/447) 27·1% (21·4 to 33·4; 61/225) 0·2% (–7·1 to 7·1)
Post-primary EPI vaccine GMC†
Anti-pertussis toxoid, IU/mL 50·95 (43·13 to 60·20; 447) 61·82 (49·58 to 77·09; 225) 0·82 (0·62 to 1·09)‡
Anti-fimbriae 2/3, IU/mL 317·97 (275·91 to 366·45; 447) 324·87 (267·34 to 394·78; 225) 0·98 (0·77 to 1·25)‡
EPI vaccine seroresponse after booster vaccination*
Anti-measles IgG ≥150 mIU/mL 89·6% (86·4 to 92·4; 381/425) 88·0% (82·8 to 92·1; 183/208) 1·7% (–3·3 to 7·4)
Anti-rubella IgG ≥4 IU/mL 99·1% (97·6 to 99·7; 421/425) 98·1% (95·2 to 99·5; 204/208) 1·0% (–0·9 to 4·0)
Anti-yellow fever neutralising antibody titre ≥8 99·1% (97·6 to 99·7; 420/424) 96·6% (93·2 to 98·6; 201/208) 2·4% (0·2 to 5·9)
References to the assays used are in the appendix (p 5). EPI=Expanded Programme on Immunization. GMC=geometric mean concentration. IU=international units. 
PHiD-CV=pneumococcal polysaccharide protein D-conjugate vaccine (Synflorix). SIIPL-PCV=Serum Institute of India candidate ten-valent pneumococcal conjugate 
vaccine. *Data are % (95% CI; number of infants with seroresponse/total number of infants). †Data are GMC (95% CI; total number of infants). ‡Data are GMC ratio 
(95% CI).
Table 2: Antibody responses to EPI vaccines after co-administration with SIIPL-PCV or PHiD-CV
OPA seroresponse* OPA GMTs
SIIPL-PCV† PHiD-CV† Difference (95% CI) SIIPL-PCV‡ PHiD-CV‡ GMT ratio (95% CI)
Serotype 1 92·7% (88·7 to 95·6; 
229/247)
75·5% (69·7 to 80·7; 
188/249)
17·2% (11·0 to 23·6) 85·2 (71·3 to 101·7; 
247)
27·6 (23·0 to 33·1; 
249)
3·09 (2·40 to 3·98)
Serotype 5 98·8% (96·5 to 99·8; 
244/247)
96·0% (92·7 to 98·1; 
239/249)
2·8% (–0·0 to 6·2) 161·3 (139·9 to 186·0; 
247)
115·9 (98·9 to 136·0; 
249)
1·39 (1·12 to 1·72)
Serotype 6B 95·9% (92·6 to 98·0; 
233/243)
86·5% (81·6 to 90·5; 
212/245)
9·4% (4·5 to 14·6) 913·5 (746·0 to 1118·7; 
243)
467·7 (365·3 to 598·7; 
245)
1·95 (1·42 to 2·69)
Serotype 7F 100% (98·5 to 100·0; 
247/247)
99·6% (97·8 to 100·0; 
249/250)
0·4% (–1·1 to 2·2) 1833·7 (1612·3 to 2085·5; 
247)
1586·8 (1392·6 to 1807·9; 
250)
1·16 (0·96 to 1·39)
Serotype 9V 100% (98·5 to 100·0; 
242/242)
100% (98·5 to 100·0; 
249/249)
0·0% 141·7 (113·4 to 177·2; 
242)
376·8 (324·0 to 438·1; 
249)
0·38 (0·29 to 0·49)
Serotype 14 97·1% (94·2 to 98·8; 
237/244)
98·0% (95·3 to 99·3; 
242/247)
–0·8% (–4·0 to 2·2) 1019·3 (816·5 to 1272·5; 
244)
1102·6 (878·6 to 1383·9; 
247)
0·92 (0·67 to 1·27)
Serotype 19F 96·8% (93·7 to 98·6; 
239/247)
98·4% (96·0 to 99·6; 
246/250)
–1·6% (–4·9 to 1·2) 594·3 (510·0 to 692·5; 
247)
895·4 (785·0 to 1021·4; 
250)
0·66 (0·54 to 0·81)
Serotype 23F 100% (98·5 to 100·0; 
246/246)
100% (98·5 to 100·0; 
243/243)
0·0% 767·2 (649·0 to 907·1; 
246)
253·1 (197·1 to 325·0; 
243)
3·03 (2·25 to 4·09)
Serotype 6A§ 97·2% (94·3 to 98·9; 
240/247)
14·9%¶ (10·7 to 20·1; 
36/241)
82·2% (76·7 to 86·6) 1317·2 (1109·4 to 1563·9; 
247)
7·1¶ (5·8 to 8·6; 
241)
186 (144 to 241)
Serotype 19A§ 92·3% (88·3 to 95·3; 
228/247)
39·0%¶ (32·7 to 45·5; 
92/236)
53·3% (46·0 to 60·1) 148·6 (121·4 to 182·0; 
247)
11·1¶ (9·2 to 13·4; 
236)
13·4 (10·2 to 17·7)
OPA=opsonophagocytic activity. GMTs=geometric mean titres. PHiD-CV=pneumococcal polysaccharide protein D-conjugate vaccine (Synflorix). SIIPL-PCV=Serum Institute of India’s candidate ten-valent pneumococcal 
conjugate vaccine. *Seroresponse was defined as OPA titres of at least 8. †Data are proportion of infants with seroresponse (95% CI; number of infants with seroresponse/total number of infants). ‡Data are GMT (95% CI; 
total number of infants). §Serotypes not included in PHiD-CV. ¶Cross-reactive responses to serotype 6B and 19F in PHiD-CV.
Table 3: Opsonophagocytic activity 4 weeks after the three-dose primary vaccination series
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Post-primary OPA seroresponse rates ranged from 
92·3% (88·3–95·3) for serotype 19A to 100·0% (95% CI 
98·5–100·0) for serotypes 7F, 9V, and 23F after SIIPL-PCV, 
and from 75·5% (69·7–80·7) for serotype 1 to 100·0% 
(98·5–100·0) for serotypes 9V and 23F after PHiD-CV 
(table 3). Among the shared serotypes, the OPA 
seroresponse rates for serotypes 1 and 6B were higher 
after SIIPL-PCV than after PHiD-CV. Compared with 
after PHiD-CV, OPA GMTs after SIIPL-PCV were higher 
for serotypes 1, 5, 6B, and 23F and lower for serotypes 9V 
and 19F.
In both groups, a significant booster response was 
demonstrated for all serotypes except serotype 5 on the 
basis of IgG GMC ratios (table 4), and for all serotypes 
on the basis of OPA GMT ratios (appendix p 19). Among 
the shared serotypes, post-booster IgG GMCs were 
higher in the SIIPL-PCV group than the PHiD-CV 
group for serotypes 1, 5, 6B, 7F, 14, and 23F and were 
higher in the PHiD-CV group than the SIIPL-PCV 
group for serotypes 9V and 19F (table 4). The OPA 
GMTs were higher in the SIIPL-PCV group than the 
PHiD-CV group for serotypes 1, 6B, 7F, 14, and 23F 
(appendix p 19).
The distributions in serotype-specific IgG concen-
trations after both vaccines were similar, as shown by 
the reverse cumulative distribution curves, which 
generally ran in parallel after both primary and 
booster vaccination (appendix p 20). The variability in 
serotype 6B con centrations after the primary vaccination 
series was high compared with that in the other sero-
types, but this was consistent between groups and was 
reduced after booster vaccination. Among the shared 
serotypes, variability in OPA titres after primary 
vaccination was relatively greater for serotype 1 
after PHiD-CV and for serotype 9V after SIIPL-PCV 
(appendix p 20). These differences were reduced after 
booster vaccination.
Among the infants randomly selected to have solicited 
adverse events collected, 377 (50·2%) of 751 in the 
SIIPL-PCV group and 203 (55·8%) of 364 in the PHiD-CV 
group had at least one solicited injection-site reaction 
after any primary series vaccination (table 5). All injection-
site adverse events were mild (grade 1) to moderate 
(grade 2). Induration rates were significantly higher with 
PHiD-CV (9·3%) than with SIIPL-PCV (4·9%). There 
were no other significant differences between groups.
About two-thirds of participants in each group 
(496 [66·0%] in the SIIPL-PCV group and 240 [65·9%] in 
the PHiD-CV group) had at least one solicited systemic 
reaction after any primary series vaccination (table 5). Of 
these, fever was the most frequent and was observed in 
more than half of the participants in both groups. 
Altogether, five (0·7%) of 751 participants had any 
grade 3 systemic reaction after SIIPL-PCV compared 
with four (1·1%) of 364 after PHiD-CV. The rates of local 
and systemic reactions were lower after the booster 











GMC ratio (95% CI)
Serotype 1 4·05 (3·76 to 4·36; 
424)
5·71 (5·25 to 6·21; 
424)
1·41 (1·31 to 1·52) 2·12 (1·88 to 2·38; 
208)
2·47 (2·19 to 2·80; 
208)
1·17 (1·06 to 1·28) 2·34 (2·02 to 2·71)
Serotype 5 1·49 (1·39 to 1·59; 
424)
1·31 (1·21 to 1·41; 
424)
0·88 (0·81 to 0·95) 1·26 (1·14 to 1·38; 
207)
0·84 (0·76 to 0·93; 
207)
0·67 (0·61 to 0·74) 1·57 (1·38 to 1·79)
Serotype 6B 1·29 (1·13 to 1·48; 
422)
8·32 (7·70 to 8·99; 
422)
6·43 (5·70 to 7·26) 1·15 (0·94 to 1·41; 
208)
4·44 (4·00 to 4·93; 
208)
3·85 (3·23 to 4·59) 1·89 (1·65 to 2·15)
Serotype 7F 3·12 (2·89 to 3·37; 
424)
6·36 (5·87 to 6·89; 
424)
2·04 (1·89 to 2·19) 2·49 (2·22 to 2·79; 
208)
4·07 (3·67 to 4·52; 
208)
1·63 (1·47 to 1·82) 1·57 (1·37 to 1·80)
Serotype 9V 1·29 (1·20 to 1·39; 
423)
1·80 (1·67 to 1·94; 
423)
1·39 (1·29 to 1·50) 1·43 (1·28 to 1·60; 
208)
2·08 (1·87 to 2·31; 
208)
1·46 (1·31 to 1·62) 0·87 (0·76 to 0·99)
Serotype 14 5·06 (4·57 to 5·62; 
419)
6·84 (6·08 to 7·68; 
419)
1·35 (1·21 to 1·51) 3·86 (3·25 to 4·57; 
203)
4·67 (3·92 to 5·55; 
203)
1·21 (1·03 to 1·42) 1·48 (1·21 to 1·82)
Serotype 19F 4·16 (3·85 to 4·48; 
414)
6·18 (5·70 to 6·71; 
414)
1·49 (1·36 to 1·63) 6·31 (5·51 to 7·24; 
203)
9·79 (8·77 to 10·92; 
203)
1·55 (1·38 to 1·75) 0·63 (0·55 to 0·73)
Serotype 23F 1·65 (1·50 to 1·80; 
423)
4·11 (3·75 to 4·50; 
423)
2·50 (2·29 to 2·72) 0·94 (0·80 to 1·11; 
208)
2·15 (1·90 to 2·44; 
208)
2·29 (1·98 to 2·65) 1·91 (1·63 to 2·24)
Serotype 6A* 1·09 (0·98 to 1·22; 
423)
4·86 (4·40 to 5·38; 
423)
4·46 (4·01 to 4·96) 0·12† (0·11 to 0·14; 
208)
0·42† (0·36 to 0·50; 
208)
3·49 (2·97 to 4·11) 11·6 (9·67 to 14·0)
Serotype 19A* 1·50 (1·37 to 1·64; 
421)
3·97 (3·63 to 4·33; 
421)
2·64 (2·40 to 2·91) 0·26† (0·23 to 0·31; 
204)
0·95† (0·79 to 1·15; 
204)
3·60 (2·99 to 4·33) 4·22 (3·52 to 5·06)
Data are GMC (95% CI; total number of infants) unless otherwise indicated. Serotype-specific IgG GMCs were measured 4 weeks after the three-dose primary vaccination series and 4 weeks after the booster dose 
at age 9 months. GMC=geometric mean concentration. PHiD-CV=pneumococcal polysaccharide protein D-conjugate vaccine (Synflorix). SIIPL-PCV=Serum Institute of India candidate ten-valent pneumococcal 
conjugate vaccine. *Serotypes not included in PHiD-CV. †Cross-reactive responses to serotype 6B and 19F in PHiD-CV.
Table 4: Serotype-specific IgG responses after the primary vaccination series and booster dose
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vaccination than after the primary vaccinations. There 
were no notable differences in type or frequency of 
solicited systemic adverse events between groups at any 
point.
More than three-quarters of infants in each group 
(1131 [75·2%] of 1503 in the SIIPL-PCV group and 
572 [76·6%] of 747 in the PHiD-CV group) had at least one 
unsolicited adverse event (appendix p 22). 36 (2·4%) 
participants in the SIIPL-PCV group and 18 (2·4%) in the 
PHiD-CV group had a serious adverse event (appendix 
p 23); none were considered related to vaccination. Three 
infants died during the study: one in the SIIPL-PCV group 
from serotype 10A pneumococcal meningitis and two in 
the PHiD-CV group from pneu monia. The deaths 
were not considered to be related to the study vaccine or 
protocol.
Discussion
This phase 3 trial was designed to show that SIIPL-PCV 
meets the specifications set out in the WHO Technical 
Report Series for the clinical assessment of PCVs and the 
target product profile, which defines the criteria that new 
PCVs must meet to secure purchase for Gavi-supported 
countries.11,26 All three primary immuno genicity objec-
tives and the safety objectives were met. First, the 
three lots of SIIPL-PCV assessed were immunologically 
equivalent on the basis of GMC ratios. Second, the 
immunogenicity of SIIPL-PCV was non-inferior to that 
of PHiD-CV. All eight of the matched serotypes in the 
two vaccines met the criteria for defining non-inferiority 
on the basis of both seroresponse rates and GMC ratios. 
Responses to serotypes 6A and 19A, the non-matched 
serotypes in SIIPL-PCV, achieved the same criteria when 
compared with serotype 6B, the serotype with the lowest 
sero response rate in the PHiD-CV group. Booster 
responses were generated for all serotypes except 
serotype 5 after both SIIPL-PCV and PHiD-CV on the 
basis of IgG GMCs, and for all serotypes on the basis of 
OPA GMTs. Third, the study demonstrated 
non-inferiority of the immune responses induced by the 
EPI vaccines after co-administration with SIIPL-PCV 
compared with after co-administration with PHiD-CV. 
Finally, SIIPL-PCV had a similar safety and tolerability 
profile to PHiD-CV.
In a double-blind, randomised, controlled trial in 
South America, the efficacy of PHiD-CV was 100% 
(95% CI 74–100) against vaccine-type IPD, 18% (5–29) 
against bacterial community-acquired pneumonia, and 
68% (17–87) against vaccine-type acute otitis media.13 In a 
study in Finland, infants received PHiD-CV according to a 
3+1 schedule that was similar to the one used in this trial, 
and the effectiveness of the vaccine was 100% (83–100) 
against vaccine-type IPD.14 Additionally, a clear reduction 
in IPD incidence after PHiD-CV introduction was 
reported in Kenya.16 The adjusted incidence rate ratio, 
comparing the periods before and after vaccine 
introduction, for vaccine-type IPD was 0·08 (95% CI 
0·03–0·22), and for all IPD (ie, vaccine and non-vaccine 
type) it was 0·32 (0·17–0·60). The adjusted incidence rate 
ratio for radiologically confirmed pneumonia was 0·52 
(0·32–0·86), and for clinically defined pneumonia it 
was 0·73 (0·54–0·97).15 The introduction of PHiD-CV into 
the routine immunisation schedule at ages 6, 10, and 
14 weeks in Kenya was accompanied by a catch-up 
campaign targeting children younger than 5 years, which 
is likely to have accelerated vaccine effects. Nonetheless, 
the data indicate that PHiD-CV confers protection against 
both invasive and mucosal pneumococcal disease after an 
infant schedule in a low-income, sub-Saharan African 
setting that is similar to The Gambia.15,16
On the basis of the finding of non-inferior immuno-
genicity, we expect that SIIPL-PCV will be effective 
against IPD in infancy—the age group and endpoint for 
which the serological correlate has been established.26,27 
The findings are further supported by the similar or 
higher OPA seroresponse rates generated by SIIPL-PCV, 
which  might ultimately be a better correlate of protection 
against IPD than the serotype-specific IgG concen-
trations.28 Correlates of protection against mucosal 
disease, including pneumonia and acute otitis media, 
have not been established, although the levels of serum 
antibody required are generally believed to be higher 
than those required to prevent IPD.29 The non-inferiority 
of SIIPL-PCV compared with PHiD-CV based on GMC 
ratios, the closely aligned reverse cumulative distribution 
curves, the similar or higher OPA GMTs for the shared 
Three-dose primary vaccination series Booster vaccination
SIIPL-PCV (n=751) PHiD-CV (n=364) SIIPL-PCV (n=428) PHiD-CV (n=213)
Injection-site adverse event*
Any 377 (50·2%) 203 (55·8%) 35 (8·2%) 15 (7·0%)
Tenderness 369 (49·1%) 193 (53·0%) 33 (7·7%) 13 (6·1%)
Erythema or redness 33 (4·4%) 19 (5·2%) 0 0
Induration or swelling 37 (4·9%)† 34 (9·3%)† 5 (1·2%) 4 (1·9%)
Systemic adverse event
Any 496 (66·0%) 240 (65·9%) 51 (11·9%) 29 (13·6%)
Grade ≥3 5 (0·7%) 4 (1·1%) 0 0
Cutaneous rash 40 (5·3%) 19 (5·2%) 4 (0·9%) 2 (0·9%)
Grade ≥3 0 1 (0·3%) 0 (0·0%) 0
Fever (≥37·5°C)‡ 391 (52·1%) 187 (51·4%) 24 (5·6%) 16 (7·5%)
Grade ≥3 (≥39·1°C) 3 (0·4%) 2 (0·5%) 1 (0·2%) 0
Irritability 240 (32·0%) 109 (29·9%) 13 (3·0%) 6 (2·8%)
Grade ≥3 2 (0·3%) 0 0 0
Drowsiness 48 (6·4%) 21 (5·8%) 10 (2·3%) 5 (2·3%)
Grade ≥3 1 (0·1%) 0 1 (0·2%) 0
Decreased appetite 47 (6·3%) 26 (7·1%) 3 (0·7%) 2 (0·9%)
Grade ≥3 2 (0·3%) 1 (0·3%) 0 0
Data are n (%). Solicited adverse event grading was completed as per appendix p 7. SIIPL-PCV=Serum Institute of India 
candidate ten-valent pneumococcal conjugate vaccine. PHiD-CV=pneumococcal polysaccharide protein D-conjugate 
vaccine (Synflorix). *No grade 3 or worse solicited injection site adverse events occurred in the study. †p=0·0032 
(Cochran-Mantel-Haenszel test stratified on field site); no other differences were significant. ‡Temperature measured 
in the axilla.
Table 5: Participants with solicited adverse events in the 7 days from the day of vaccination
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serotypes, as well as the robust booster responses, 
suggest SIIPL-PCV will also affect mucosal pneumococcal 
disease, although studies should be done after imple-
mentation to demonstrate this.
Before efficacy data for PHiD-CV became available, the 
vaccine was assessed for immunological non-inferiority 
to the licensed seven-valent PCV (Prevenar; Pfizer), for 
which efficacy had already been established.23 PHiD-CV 
was non-inferior to Prevenar for all shared serotypes 
except serotypes 6B and 23F, whereas the OPA 
seroresponse rates were similar for all serotypes. The 
efficacy of PHiD-CV against IPD caused by serotype 6B 
was 100% (95% CI 55–100) in the Finnish study; 
therefore, the lower antibody responses elicited by 
PHiD-CV than by Prevenar against this serotype have not 
had a demonstrable clinical impact.14,23 In our trial, the 
responses to serotypes 6B and 23F after SIIPL-PCV were 
higher than the responses after PHiD-CV, both after the 
primary vaccination series and the booster dose, 
supporting the expectation that SIIPL-PCV will be 
effective against these serotypes.
A limitation of using PHiD-CV as the comparator 
vaccine in this study is the consequent absence of 
matched responses for serotypes 6A and 19A in 
SIIPL-PCV. On the basis of the guidance set out in the 
WHO Technical Report Series, responses to the 
two serotypes were compared with responses to 
serotype 6B—the serotype with the lowest seroresponse 
rate following PHiD-CV. This approach tends to favour 
the new vaccine. Therefore, although the prespecified 
criteria for establishing non-inferiority of SIIPL-PCV 
compared with PHiD-CV were achieved, caution is 
warranted in interpreting these findings in isolation as 
the basis on which to predict efficacy against the 
two non-matched serotypes. Descriptive data from the 
phase 1/2 study of SIIPL-PCV done in The Gambia 
suggest the immunogenicity of the vaccine against these 
serotypes is somewhat lower than that of PCV13.9 
Nonetheless, the IgG GMCs generated by SIIPL-PCV in 
our study were 1·00 μg/mL (95% CI 0·95 to 1·06) against 
serotype 6A and 1·64 μg/mL (1·57 to 1·72) against 
serotype 19A. The point estimates in both cases are 
greater than the serotype-specific correlates of protection 
estimated for the same serotypes, even though they are 
based on UK data (0·16 μg/mL [0·08 to 1·05] against 
serotype 6A and 1·00 μg/mL [0·60 to 2·47] against 
serotype 19A).30 Additionally, in settings incorporating a 
booster dose of the vaccine into their schedule, 
serotypes 6B and 19F in PHiD-CV have been shown to 
provide a level of cross-protective immunity against IPD 
caused by serotypes 6A and 19A. In Brazil, the 
effectiveness of PHiD-CV against IPD caused by 
serotype 19A was 82·2% (95% CI 10·7 to 96·4), although 
no significant protection was demonstrated against 
serotype 6A in that setting (14·7% [–311·6 to 82·3]).31,32 In 
Canada, the effectiveness against serotype 19A was 76% 
(95% CI 7 to 94).33 A population-based study in Finland 
reported a non-significant reduction of 26% (95% CI 
–13 to 51) in serotype 19A IPD and a reduction of 95% 
(75 to 100) in serotype 6A IPD 6 years after introduction 
of PHiD-CV. Any protection against serotype 19A in this 
population appeared predominately in infants younger 
than 2 years.34,35 Thus, although the data on cross-
protection are somewhat heterogenous, the IgG GMCs 
generated by SIIPL-PCV in this study were more than 
five-times higher and the OPA GMTs more than 
ten-times higher than the cross-reactive responses 
generated by PHiD-CV. Although follow-up studies are 
warranted, the data support the expected effect of 
SIIPL-PCV on serotype 6A and 19A IPD.
Immune responses to the EPI vaccines were non-inferior 
when the vaccines were co-administered with SIIPL-PCV 
compared with when they were co-administered with 
PHiD-CV. PHiD-CV is licensed for co-administration with 
all EPI vaccines that were assessed in this trial except yellow 
fever, for which no data are available. However, given the 
seroresponse rate to yellow fever when co-administered 
with SIIPL-PCV was greater than 99%, clinically significant 
differences in the yellow fever seroresponse rates after co-
administration of the two vaccines are unlikely. At about 
27%, the seroresponse rate to rotavirus was low irrespective 
of group, reflecting the generally low immunogenicity and 
efficacy of rotavirus vaccines in LMICs.36
The tolerability and safety of SIIPL-PCV and PHiD-CV 
were compared on the basis of the occurrence of solicited 
and unsolicited adverse events. The proportion of children 
with injection-site swelling was lower after primary 
vaccination with SIIPL-PCV than after primary vaccination 
with PHiD-CV, but otherwise the safety profiles of the 
two vaccines were similar. Three infants died during the 
trial, unrelated to the trial vaccines or to trial participation. 
This number of deaths is somewhat lower than might 
have been predicted on the basis of a post-neonatal 
mortality rate of eight deaths per 1000 livebirths in urban 
regions of The Gambia.37 It probably reflects the exclusion 
of infants with clinically significant health complaints 
identified at screening and the availability of a clinician 
to assess and provide care for enrolled participants 
throughout the trial.
The trial has several strengths. It was designed to meet 
the requirements established for a PCV to achieve WHO 
prequalification and used non-inferiority criteria that 
were aligned with those used in the pivotal phase 3 trials 
of the two licensed and prequalified second-generation 
PCVs.23,25 Based on the data presented, SIIPL-PCV 
achieved WHO prequalification in December, 2019, and 
is thus available to Gavi-supported countries and for 
purchase by UNICEF and other agencies. Data for the 
week 6, 10, and 14 schedule can reasonably be extrapolated 
to schedules starting later and having a wider dosing 
interval, making the results of the trial applicable to more 
relaxed schedules. The trial achieved high retention rates 
and few infants were excluded from the per-protocol 
population as a result of protocol deviations, ensuring a 
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high degree of confidence in the study findings. 
Conducting the study in The Gambia maximised the 
relevance of the data for similar LMICs, where the 
potential value of the vaccine is likely to be greatest. The 
eligibility criteria aimed to exclude infants with clinically 
significant underlying health complaints in order to 
maximise the probability of detecting genuine safety 
signals. Nonetheless, the findings are expected to be 
broadly applicable to the infant population. The 
equivalence margins used were at least as stringent as 
those used to support licensure of other PCVs and 
suggest an absence of meaningful differences between 
lots.23,24 Finally, although the limitations related to 
serotypes 6A and 19A have been noted, the use of 
PHiD-CV as the reference vaccine ensures that 
immunobridging for the other serotypes is directly to 
efficacy data generated in randomised controlled trials, 
which reduces the risk of the so-called biocreep associated 
with the conduct of serial non-inferiority trials based on 
immunogenicity alone.38
The trial has some additional limitations. First, although 
use of IgG seroresponse rates as a correlate of protection 
is well established and recommended by WHO, the 
marker has been defined on the basis of its value in pre-
dicting population-level protection from IPD in infancy. It 
does not account for potential serotype-specific differences 
in strain susceptibility to antibodies and does not a 
priori predict protection from mucosal disease.30 The 
antibody distributions and functional antibody responses 
suggest SIIPL-PCV will effect these disease endpoints. 
Nonetheless, the limitations of using any one serological 
marker in isolation to predict disease effect should be 
noted and the importance of generating robust post-
implementation effectiveness data emphasised.
Since Rwanda and The Gambia became the first 
sub-Saharan African countries to introduce PCV into 
their national EPI schedules in 2009, there has been 
substantial progress in PCV rollout. Nonetheless, recent 
estimates suggest that more than 60% of children 
younger than 5- years remain unvaccinated globally, with 
the bulk of vaccine-preventable pneumococcal deaths 
occurring across Africa and southeast Asia.3 In all, PCVs 
are expected to have accounted for more than 40% of 
Gavi expenditure on vaccines between 2016 and 2020.8 
Furthermore, although the price of available PCVs has 
decreased, countries that are no longer eligible for Gavi 
support, as well as middle-income countries that have 
delayed PCV introduction, face substantial financial 
constraints. The data generated in this trial have 
supported the licensure and WHO prequalification of 
SIIPL-PCV and suggest the vaccine will have an impact 
on pneumococcal disease globally.
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